NEW YORK (GenomeWeb) – MBio Diagnostics, a developer of point-of-care diagnostic and sample testing technologies, announced on Thursday that it has closed a $6.3 million Series B round of financing.
The company said that the proceeds of the round will be used to refine its multiplex analyzer platform, which is based on proprietary planar waveguide and fluorescent detection technology, and make improvements to its manufacturing. The Boulder, Colorado-based firm said the system can detect a variety of analytes including proteins, cells, nucleic acids, and small molecules.
The money will also support MBio's efforts to find new commercial partners, CEO Chris Myatt said in a statement.